Vytorin Derivative Suit Settlement Wins Initial Nod

Law360, New York (January 10, 2012, 6:59 PM EST) -- A New Jersey federal judge on Tuesday preliminarily approved a settlement in a shareholder derivative suit accusing former Schering-Plough Corp. directors of hiding the lackluster performance of the Merck & Co. Inc. unit's anti-cholesterol drug Vytorin for nearly two years after a clinical trial.

U.S. District Judge Dennis M. Cavanaugh signed off on the terms of the settlement, which include requirements that Merck Research Laboratories must divulge any such delays in reporting the results of clinical trials to the research committee of Merck’s board of directors,...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

CAIN v. HASSAN et al


Case Number

2:08-cv-01022

Court

New Jersey

Nature of Suit

Securities/Commodities

Judge

Dennis M. Cavanaugh

Date Filed

February 25, 2008

Law Firms

Companies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.